Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Subscribe To Our Newsletter & Stay Updated
